We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Exercise on Elevated C-reactive Protein Concentrations in Formerly Inactive Adults

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00113061
First Posted: June 6, 2005
Last Update Posted: July 29, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
  Purpose
The purpose of this study is to determine the effect of exercise training on elevated C-reactive protein (CRP) concentrations, an indicator of inflammation, in initially inactive women and men.

Condition Intervention
Cardiovascular Diseases Heart Diseases Obesity Procedure: Exercise

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
Official Title: INFLAME: Inflammation and Exercise

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • Plasma CRP concentration (measured at Month 4)

Secondary Outcome Measures:
  • Changes in visceral adiposity, the cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and heart rate variability (measured at Month 4)

Estimated Enrollment: 162
Study Start Date: July 2004
Study Completion Date: June 2006
Detailed Description:

BACKGROUND:

CRP, a marker of systemic inflammation, has been reported to be an independent predictor of cardiovascular disease in both women and men. Recently published data from cross-sectional analyses showed that CRP is inversely related to cardiorespiratory fitness, and that this association is independent of body mass index. Regular exercise may affect CRP levels, and can possibly be used as a means of reducing elevated CRP levels. Though there are a number of studies focusing on related topics, there are no published reports from randomized clinical trials on the effect of exercise training alone on CRP levels.

DESIGN NARRATIVE:

An estimated 200 individuals will be randomly assigned to either a no exercise control group or an exercise group. Exercising individuals will participate in 3 or 4 training sessions each week for 4 months, and will progress to a total energy expenditure of 16 kcal [kg(-1), week(-1)], which is an exercise dose at the upper end of current public health recommendations for physical activity. The target exercise intensity will be 50-70% of baseline volume of oxygen consumed (V02 max). VO2 max is the maximal rate of oxygen consumption during exercise, and is a measurement of fitness. The primary outcome measure will be plasma CRP concentration. Secondary outcomes will be changes in variables that are potential mechanisms through which regular exercise might reduce CRP. These variables include visceral adiposity, the cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), and heart rate variability as a measure of autonomic balance. Although the primary outcome is CRP level, this study will also contribute significantly to the limited body of literature examining the effect of exercise on the variables of visceral adiposity, cytokines, and heart rate variability.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Physically inactive
  • C-reactive protein level at least 2.0 mg/L but less than 10.0 mg/L upon study entry
  • Body mass index between 18.5 kg/square meter and 40.0 kg/square meter as measured at study entry
  • Does not smoke
  • Total cholesterol at least 240 mg/dl with LDL-C at least 160 mg/dl OR LDL less than 190 mg/dl and Framingham less than 10%
  • Triglyceride levels no higher than 300 mg/dl
  • Fasting glucose level less than 126
  • Systolic blood pressure less than 140 mm Hg and/or diastolic blood pressure less than 90 mm Hg as measured at study entry
  • If taking an oral contraceptive, aspirin, ibuprofen, or other anti-inflammatory medications, must be on a stable dose for 6 months prior to study entry
  • If taking a cholesterol medication, including statins, blood pressure medication (including ace inhibitors), or multi-vitamins, must be on a stable dose for 2 months prior to study entry

Exclusion Criteria:

  • Using a beta blocker, hormone replacement therapy, or corticosteroids (except inhalers)
  • Any rheumatologic, orthopedic, neurological, or autoimmune diseases, or seizure disorder
  • Any significant cardiovascular disease or disorders including, but not limited to, stent or coronary artery bypass grafting
  • Cardiac dysrhythmias including, but not limited to, left bundle branch block, atrial fibrillation, pacemaker, or automatic implantable cardioverter defibrillator
  • Any surgery, broken bones, blood donation, or anaphylactic shock within 6 months of study entry
  • Any sprain or strain, removal of wisdom teeth, or use of antibiotics within 3 months of study entry
  • History of stroke or TIA
  • History of cancer within at least 5 years of study entry
  • Diabetes or glucose intolerance
  • Planning on participating in any other research trials during the next year
  • Currently pregnant
  • Planning to becoming pregnant during the next year
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00113061


Locations
United States, Louisiana
Pennington Biomedical Research Center, LSU System
Baton Rouge, Louisiana, United States, 70808
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Timothy S. Church Pennington Biomedical Research Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00113061     History of Changes
Other Study ID Numbers: 180
R01HL075442 ( U.S. NIH Grant/Contract )
First Submitted: June 3, 2005
First Posted: June 6, 2005
Last Update Posted: July 29, 2016
Last Verified: December 2007

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):
Coronary Heart Disease Risk Reduction

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases